Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Type 2 Diabetes Mellitus (DM)

NCT03597412 is registered in ClinicalTrials.gov with Yuhan Corporation as lead sponsor.

NCT NCT03597412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03597412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Atherosclerotic Cardiovascular Disease (ASCVD) Patients With Type 2 Diabetes Mellitus (DM)
Lead sponsor
Yuhan Corporation
Phase
Phase 4
Overall status
Completed
Start date
October 17, 2018
Completion date
August 12, 2020
Enrollment
236 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerotic cardiovascular disease, type 2 diabetes mellitus